Page 52 - Demo

Chapter 250References1. Hickman RA, O’Shea SA, Mehler MF, Chung WK. Neurogenetic disorders across the lifespan: from aberrant development to degeneration. Nat Rev Neurol. Feb 2022;18(2):117-124. doi:10.1038/s41582-021-00595-52. Saudubray JM, Garcia-Cazorla A. An overview of inborn errors of metabolism affecting the brain: from neurodevelopment to neurodegenerative disorders. Dialogues Clin Neurosci. Dec 2018;20(4):301-325. doi:10.31887/DCNS.2018.20.4/jmsaudubray3. Morato Torres CA, Wassouf Z, Zafar F, Sastre D, Outeiro TF, Schüle B. The Role of AlphaSynuclein and Other Parkinson’s Genes in Neurodevelopmental and Neurodegenerative Disorders. International journal of molecular sciences. 2020;21(16):5724. doi:10.3390/ijms211657244. Puschmann A. New Genes Causing Hereditary Parkinson’s Disease or Parkinsonism. Curr Neurol Neurosci Rep. Sep 2017;17(9):66. doi:10.1007/s11910-017-0780-85. Morales-Briceno H, Mohammad SS, Post B, et al. Clinical and neuroimaging phenotypes of genetic parkinsonism from infancy to adolescence. Brain. Dec 4 2019;doi:10.1093/brain/awz3456. Niemann N, Jankovic J. Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. Parkinsonism Relat Disord. Oct 2019;67:74-89. doi:10.1016/j.parkreldis.2019.06.0257. Wiseman FK, Al-Janabi T, Hardy J, et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci. Sep 2015;16(9):564-74. doi:10.1038/nrn39838. Finucane BM, Myers SM, Martin CL, Ledbetter DH. Long overdue: including adults with brain disorders in precision health initiatives. Curr Opin Genet Dev. Dec 2020;65:47-52. doi:10.1016/j.gde.2020.05.0019. Fortea J, Vilaplana E, Carmona-Iragui M, et al. Clinical and biomarker changes of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study. Lancet. Jun 27 2020;395(10242):1988-1997. doi:10.1016/s0140-6736(20)30689-910. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and metaanalysis protocols (PRISMA-P) 2015 statement. Syst Rev. Jan 1 2015;4:1. doi:10.1186/2046-4053-4-111. Köhler S, Carmody L, Vasilevsky N, et al. Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources. Nucleic Acids Res. Jan 8 2019;47(D1):D1018-d1027. doi:10.1093/nar/gky110512. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. Oct 2015;30(12):1591-601. doi:10.1002/mds.2642413. Study Quality Assessment Tools. National Institutes of Health. Accessed April, 2020. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools14. Zschocke J. HSD10 disease: clinical consequences of mutations in the HSD17B10 gene. J Inherit Metab Dis. Jan 2012;35(1):81-9. doi:10.1007/s10545-011-9415-415. Lake NJ, Bird MJ, Isohanni P, Paetau A. Leigh syndrome: neuropathology and pathogenesis. J Neuropathol Exp Neurol. Jun 2015;74(6):482-92. doi:10.1097/nen.000000000000019516. Trifunovic A, Wredenberg A, Falkenberg M, et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature. May 27 2004;429(6990):417-23. doi:10.1038/nature0251717. Rahman S, Copeland WC. POLG-related disorders and their neurological manifestations. Nat Rev Neurol. Jan 2019;15(1):40-52. doi:10.1038/s41582-018-0101-018. Burke EA, Frucht SJ, Thompson K, et al. Biallelic mutations in mitochondrial tryptophanyltRNA synthetase cause Levodopa-responsive infantile-onset Parkinsonism. Clin Genet. Mar 2018;93(3):712-718. doi:10.1111/cge.1317219. Maynard TM, Meechan DW, Dudevoir ML, et al. Mitochondrial localization and function of a subset of 22q11 deletion syndrome candidate genes. Mol Cell Neurosci. Nov 2008;39(3):439-51. doi:10.1016/j.mcn.2008.07.027